门冬胰岛素和生物合成人胰岛素在妊娠期糖尿病治疗中的疗效及安全性

Efficacy and Safety of Insulin Aspart and Biosynthetic Human Insulin in the Treatment of Gestational Diabetes

目的分析门冬胰岛素和生物合成人胰岛素在妊娠期糖尿病治疗中的疗效与安全性。方法从该院2019年1月-2020年1月收治的妊娠期糖尿病患者中,择取90例资料完备的作为研究对象。按照盲选法将其随机分为两组,每组45例。其中采取生物合成人胰岛素治疗的患者,设置为对照组;采取门冬胰岛素治疗的患者,设置为观察组。对两组患者干预后的血糖指标进行观察,记录其血糖达标时间。同时,对两组患者的不良反应发生状况和低血糖事件发生率加以统计。结果在干预前,两组患者的空腹血糖、餐后2 h血糖比较,差异无统计学意义(P>0.05);在干预后,观察组患者的空腹血糖与餐后2 h血糖相较于对照组,改善幅度较为明显,差异有统计学意义(P<0.05)。在两组患者用药后血糖达标时间上比较,观察组明显短于对照组,差异有统计学意义(P<0.05)。通过随访,两组患者的不良妊娠状况比较,差异无统计学意义(P>0.05)。在两组患者的低血糖发生率相比,观察组低于对照组,差异有统计学意义(P<0.05)。结论门冬胰岛素与生物合成人胰岛素均能够改善妊娠期糖尿病患者的血糖指标,降低其不良妊娠结局的发生可能,但在血糖达标时间、血糖控制上,门冬胰岛素的效果更为理想,且其低血糖发生率较低,疗效与安全性显著,可加以选用。

Objective To analyze the efficacy and safety of insulin aspart and biosynthetic human insulin in the treatment of gestational diabetes.Methods From January 2019 to January 2020 in the hospital,90 cases of gestational diabetes patients with complete data were selected as the research objects.According to the blind selection method,they were randomly divided into two groups,with 45 cases in each group.Among them,patients treated with biosynthetic human insulin were set as the control group;patients treated with insulin aspart were set as the observation group.Observed the blood glucose indicators of the two groups of patients after the intervention,and recorded the time when their blood glucose reaches the standard.At the same time,the incidence of adverse reactions and the incidence of hypoglycemia events in the two groups of patients were counted.Results Before the intervention,there was no statistically significant difference in the fasting blood glucose and 2 h postprandial blood glucose between the two groups of patients(P>0.05);after the intervention,the fasting blood glucose and the 2 h postprandial blood glucose of the observation group was compared with the control group,the improvement was more obvious,and the difference was statistically significant(P<0.05).Comparing the blood glucose reaching standard time between the two groups of patients after medication,the observation group was significantly shorter than the control group,and the difference was statistically significant(P<0.05).Through follow-up,there was no statistically significant difference in the adverse pregnancy status between the two groups of patients(P>0.05).Compared with the incidence of hypoglycemia in the two groups of patients,the observation group was lower than the control group,and the difference was statistically significant(P<0.05).Conclusion Both insulin aspart and biosynthetic human insulin can improve the blood glucose index of patients with gestational diabetes and reduce the possibility of adverse pregnancy outcome.However,insulin aspart is more effective in terms of the time to reach the standard of blood glucose and the control of blood glucose,and its low incidence of hypoglycemia,significant efficacy and safety,can be selected.